Full Papers
Haemorrhage-related adverse events associated with nintedanib: a pharmacovigilance study based on the FAERS database
Q. Liu1, W. Zuo2, H. Huang3
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing; and Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. pumchhh@126.com
CER19471
Full Papers
PMID: 41678154 [PubMed]
Received: 29/10/2025
Accepted : 19/01/2026
In Press: 08/02/2026
Abstract
OBJECTIVES:
We aimed to analyse the characteristics and positive signals of haemorrhage-related adverse event (HrAE) associated with nintedanib in the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
METHODS:
The reports of adverse events (AE) associated with nintedanib as the primary suspect (PS) drug were extracted from the FAERS database from the fourth quarter of 2014 to the third quarter of 2024. HrAE were identified using the Standardized Medical Dictionary for Regulatory Activities Queries (SMQs). The characteristics of AE reports were described and multivariate analysis was used to analyse the factors related to HrAE. Disproportionality analysis was performed to detect AE signals, and a multiplicative and additive model was applied to evaluate the association between drug-drug interaction (DDI) and HrAE. Sensitivity analysis was conducted on serious AE that life-threatening and death, as well as AE reported by physician and pharmacist.
RESULTS:
A total of 3,018 patients experienced HrAE associated with nintedanib were included. There was a total of 3,929 AE reports. Compared with non-HrAE, patients age ≥65 years (p≤0.001, OR=1.675, 95% CI 1.376-2.040) and the lower daily dose (p=0.014, OR=1.001, 95% CI 1.000–1.002) were associated with HrAE. The gastrointestinal system was the most frequently affected organ and/or system. Co-administration of antiplatelet agents (ROR=6.02, 95% CI 4.76–7.62), anticoagulants (ROR=4.57, 95% CI 3.85–5.42) or prednisone (ROR=1.63, 95% CI 1.15–2.31) was more common among HrAE patients than among non-HrAE patients. Patients age ≥65 years (p=0.018, OR=1.623, 95%CI 1.088-2.420) and the time-to-onset (TTO) from drug administration to AE onset >90 days (p≤0.001, OR=2.266, 95%CI 1.744-2.944) were associated HrAE when AE reports with life-threatening or fatal were included; male (p=0.004, OR=1.004, 95% CI 1.004–1.007) is associated with HrAE when AE reports by physician or pharmacist were included.
CONCLUSIONS:
Gastrointestinal bleeding is the most commonly reported HrAE associated with nintedanib. Patients over 65 years were more likely to experience HrAE, especially in life-threatening and death AE reports.
